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Natural killer (NK) cells play an important role in the innate immune response. The
summation of activation and inhibitory signals delivered through cell surface membrane
receptors determines NK cell function. However, the continuous engagement of an
activating receptor on NK cells appears to render the cells hyporesponsive to stimulation
through other unrelated activating receptors. The mechanism by which this takes place
remains unclear. Herein we demonstrate that continuous in vivo engagement of the
Ly49H receptor with its ligand, m157, results in Ly49H+ NK cells that are hyporesponsive
to further stimulation by other ITAM-dependent and independent receptors, while
Ly49H− NK cells remain unaffected. The hyporesponsiveness of the NK cell correlates
with the degree of Ly49H receptor downmodulation on its cell surface. We observe
defects in calcium flux in the hyporesponsive NK cells following stimulation through the
NK1.1 receptor. In addition, we observe differences in signaling molecules that play a
role in calcium flux, including spleen tyrosine kinase (Syk) at baseline and phosphorylated
phospholipase C gamma 2 (p-PLCγ2) at both baseline and following stimulation through
NK1.1. We also demonstrate that various ITAM associated activation receptors, including
Ly49H, remain associated with their respective adaptor molecules. With regard to in vivo
NK cell function, we did not find differences in the formation of metastatic lung lesions
following IV injection of B16melanoma cells. However, we did observe defects in rejection
of missing-self targets in vivo. The data suggest that continuous engagement of the
Ly49H activating receptor on NK cells results in hyporesponsiveness of the NK cells to all
of the ITAM-dependent and independent receptors we analyzed due to altered signaling
pathways downstream of the receptor and adaptor molecule.
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INTRODUCTION
NK cells effector function (release of cytokines and cytotoxic
granules) is determined by the summation of stimulation
received through activating and inhibitory receptors expressed
on its cell surface (1–3). Several NK cell-activating receptors
signal through immunoreceptor tyrosine-based activation motif
(ITAM) bearing adaptor molecules. These include Ly49H and
NK1.1, which associate with DAP12 and FcRε1γ, respectively.
Engagement of the activating receptor results in phosphorylation
of tyrosine residues within the ITAM motif, which serve as
binding sites for Syk and/or Zap70, causing a downstream
signaling cascade (4). Others and we have demonstrated that
continuous engagement of the activating receptor results,
counterintuitively, in the hyporesponsiveness of murine and
human NK cells (5–8). Although this appears to be an important
mechanism in determining NK responsiveness, we do not yet
clearly understand the changes that take place within these cells
following continuous engagement of an activating receptor.
Prior studies looking at lymphokine activated killer (LAK)
cells suggest that continuous engagement of NKG2D with its
ligand H60 in vitro results in dissociation from its adaptor
molecule DAP12. In addition, the LAK cells demonstrated a
decrease in the intracellular level of a number of ITAM-associated
adaptor molecules, including DAP12 and CD3ζ (9). Continuous
engagement of NKG2D on LAK cells in vitro also resulted
in defective Ca2+ mobilization following stimulation through
multiple activating receptors including NK1.1, NKp46, and
CD16, but not Ly49D (9, 10). Furthermore, continuous
engagement of NKG2D on LAK cells resulted in defective killing
of H60 expressing and RMA/s (missing-self) targets, as well
as attenuated antibody-dependent cellular cytotoxicity (ADCC),
but no defect in killing of CHO (Ly49D ligand expressing target)
cells. Finally, continuous in vitro engagement of Ly49D on LAK
cells (by incubation with CHO cells) resulted in Ly49D+, but
not Ly49D−, LAK cells having defects in killing H60 expressing
targets, RMA/s targets, and CHO cell targets as well as antibody-
dependent cell cytotoxicity (10). This suggests a selectivity in how
continuous engagement of activating receptors results in defects
to other activating receptors.
In vivo studies addressing the continuous engagement of
NKG2D, using a transgenic mouse in which human MICA
is ubiquitously expressed under the MHC class I promoter,
conflict with prior in vitro findings (11). Defects in NK1.1-
and Ly49D-mediated killing, but not NKp46-mediated killing,
were seen following chronic NKG2D engagement. However,
IFNγ production following stimulation with plate bound NK1.1
and NKp46, but not Ly49D, revealed increased production
of the cytokine by NK cells where continuous engagement
of the NKG2D receptor took place compared to WT NK
cells (11). Thus, based on this prior study, the continuous
engagement of NKG2D in this system appeared to have opposite
effects on killing and IFNγ production mediated by other
activating receptors.
Several studies have attempted to address the role continuous
engagement of NKG2D plays in the NK cell response to
melanoma tumors in vivo. DNAM1 and natural cytotoxicity
receptors (NCRs) have been shown to be important for NK
cell mediated immunity to melanoma cells, as ligands for
NKP46, NKG2D, and DNAM1 appear to be expressed on these
malignant cells (12–14). There was no difference in growth
rate of melanoma tumors following subcutaneous injection of
B16-F10 melanoma cells in MICA-expressing transgenic mice
compared to litter mate control mice (11). Another study
demonstrated that melanoma tumor cells engineered to secrete
a soluble form of MULT1 were rejected better by NK cells
than the parental melanoma cell line, suggesting the soluble
MULT1 increases tumor rejection by enhancing NK cell function
(15). They hypothesize that expression of the NKG2D ligand
on non-tumor cells within the tumor environment results in
desensitization of the NK cells due to continuous engagement
and downregulation of theNKG2D receptor. The solubleMULT1
blocks these interactions, resulting in an increase of the NK
cell responsiveness to the tumor. Thus, the precise role that
continuous engagement of NKG2D in vivo plays in the NK
cell response to melanoma challenge, as well as the particular
activating receptors involved in this response (NKp46, DNAM1,
or others), is not entirely clear.
In this manuscript, we aim to shed light on the mechanism
by which continuous engagement of NK cell activating
receptors results in NK cell hyporesponsiveness, as well as
how this impacts NK cell response to tumor cells in vivo.
To accomplish this, we employed a transgenic mouse model
developed in our laboratory that ubiquitously expresses the
murine cytomegalovirus protein m157 under the control of
the β-actin promoter (7, 16). In this mouse (m157Tg),
the continuous engagement of m157 with Ly49H results
in systemic Ly49H downregulation and dysfunction. Using
this model, we demonstrate NK cells undergoing continuous
engagement of the Ly49H receptor are hyporesponsive to
further stimulation by a wide range of ITAM-dependent and
independent receptors. This hyporesponsiveness correlates with
the degree of Ly49H downmodulation. Hyporesponsive NK
cells demonstrated defective calcium flux upon stimulation
through the NK1.1 activating receptor. In addition, we observed
differences in the signaling molecules involved in mediating
calcium flux, including Syk and p-PLCγ2. We did not observe
any discrepancies in the intracellular levels of ITAM-containing
adaptor molecules, and they appeared to remain associated with
their respective activating receptors. In vivo, we detected defects
in killing of missing-self targets but did not find differences in
the formation of metastatic lung lesions following IV injection
of B16 melanoma cells. The data suggest that the continuous
engagement of this activating receptor on NK cells results in
hyporesponsiveness of the NK cells to multiple ITAM-dependent




The B6.ROSAm157 mouse was generated by cloning the Smith
strain MCMVm157 DNA, obtained by PCR with NotI and XhoI
ends, into pBigT to generate pBigTm157. This construct was
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digested with PacI and AscI and inserted into pROSA26-PA to
generate pROSAm157. The plasmids pBigT and pROSA26-PA
were gifts from Frank Costantini (Addgene plasmids # 21270
and # 21271; RRID:Addgene_21270 and RRID:Addgene_21271)
(17). The plasmid pROSAm157 was linearized with BbvCI and
used to target the Rosa locus in B6 Blu ES cells. Targeted clones
were injected into albino B6 host blastocysts using standard
methods. High coat color chimeric mice were bred to establish
germline transmission. B6.ROSAm157 was bred to B6.C-
Tg(CMV-cre)1Cgn/J or B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/2J
mice. The generation of a transgenic mouse constitutively
expressing m157 (m157Tg) was previously described (7). During
the generation of this line, a second founder that expressed lower
levels of m157 was also obtained (m157Tg.Low). Mice were
maintained under specific pathogen-free conditions and used
after they reached 8 weeks of age. All animals received humane
care according to the criteria outlined in the “Guide for the
Care and Use of Laboratory Animals” prepared by the National
Academy of Sciences and published by the National Institutes
of Health (NIH publication 86-23 revised 1985). The Animal
Studies Committee at Washington University (St. Louis, MO)
approved all animal studies.
Tamoxifen Treatment and NK Cell
Depletion of Mice
Mice were administered tamoxifen from Toronto Research
Company (Toronto, Canada) by intraperitoneal injection (2.5
mg/mouse/d for 3–5 consecutive days) in 100 µl of sunflower
seed oil (Sigma-Aldrich) as according to published protocols (18).
For in vivo killing experiments, NK cells were depleted from a
subset of mice by intraperitoneal injection of 100 µg α-NK1.1
(pk136) antibody on days−5 and−2. For NK cell depletion prior
to melanoma injection, mice were treated on days−4 and+3.
Antibodies and Flow Cytometry
Except where otherwise indicated, all antibodies were obtained
from Biolegend (San Diego, CA). Cell surface receptors
were labeled with NK1.1 (pk136), Ly49D (4E4, a gift from
Wayne Yokoyama), Ly49H (3D10), NKp46 (29A1.4), CD49b
(DX5), DNAM1 (10E5), IL2 receptor (IL-2Rβ), and CD3
(17A2). For intracellular staining of Syk and Zap70, cell
surface receptors were stained and the cells were fixed with
BD Cytofix/Cytoperm, the cells were permeabilized with 1%
saponin in flow cytometry buffer and stained intracellularly
for Syk (5F5) and Zap70 (1E7.2). For intracellular staining
of PLCγ2, cells were initially stained with α-Ly49H-AF647
(3D10) and α-CD49b-BV421 (DX5). The cells were fixed in 3%
paraformaldehyde in PBS and then permeabilized with absolute
methanol followed by staining with α-NKp46-PerCP-eFluor710
(29A1.4) from Thermo Fisher Scientific (Waltham, MA), α-
CD3-PE-Cy7 (17A2), α-NK1.1-AF488 (pk136), and α-PLCγ2-PE
obtained from Miltenyi (Bergisch Gladbach, Germany). Samples
were run on a BD FacsCanto, BD LSR-II, or BD Fortessa X20
(Becton Dickinson, Franklin Lakes, NJ) and analyzed using
FlowJo v10.5.3 (Becton Dickinson).
Activation Assays
Twelve well tissue culture treated plates (TPP, Trasadingen,
Switzerland) were incubated at 37◦C for 90–120min with
antibody diluted in PBS. Dilutions were as follows: α-NK1.1
(pk136) at 8µg/ml, α-NKp46 (29A1.4) at 4µg/ml, α-Ly49D
(4E5) at 32µg/ml, and α-DNAM1 (10E5) at 500 ng/ml.
Background levels of IFNγ and CD107a were measured using
PBS only coated plates. Freshly isolated splenocytes were depleted
of erythrocytes by ammonium chloride lysis, resuspended in dye-
free RPMI-1640 with 10% FBS and 5mM HEPES, and filtered
through 110 um nylon mesh. After washing the wells, 5 × 106
cells were loaded onto each well at 107 cells/ml and incubated
at 37◦C in a 5% CO2 incubator. The α-NKp46 and α-DNAM1
plates (and their respective controls) were co-stimulated with
400 IU/ml of IL2 (Chiron, Emeryville, CA). Other samples were
mono-stimulated with IL2 at 2,000 IU/ml or IL15 at 125 ng/ml
(Peprotech, Rocky Hill, NJ). After 1 h, 200 ng/ml α-CD107a-
APC (1D4B), 5µg/ml Brefeldin A, and 2µMmonensin (all from
Biolegend, San Diego, CA) were added to label surface-exposed
Lamp1 and prevent excretion of IFNγ. The assay was further
incubated for 7 h prior to being stopped by the addition of cold
flow cytometry buffer (PBS with 1% FBS and 5mM NaN3). Fc
receptors were blocked with supernatant from the hybridoma
2.4G2, and cells were surface stained with biotinylated α-Ly49H,
streptavidin-PE, α-CD49b-BV421, α-NKp46-PerCP-e710, and α-
CD3-PE-Cy7. For stimulation through Ly49D, DNAM1, IL2
receptor and IL15 receptor, NK cells were identified as NK1.1+,
NKp46+, CD3−. For stimulation through NKp46, NK cells
were identified as NK1.1+, CD49b+, CD3−. For stimulation
through NK1.1, NK cells were identified as CD49b+, NKp46+,
CD3−. Following fixation with BD Cytofix/Cytoperm, the cells
were permeabilized with 1% saponin in flow cytometry buffer
and stained intracellularly with α-IFNγ-AF488 (XMG1.2). The
samples were analyzed on a BD FacsCanto flow cytometer
(Becton Dickinson, Franklin Lakes, NJ).
Ca2+ Flux
Freshly-isolated splenocytes (5 × 106 cells/ml) were dye-loaded
for 30min at 37◦C in serum-free, phenol red-free RPMI with
0.002% Plurionic F127 and the calcium-sensitive dye, Indo1 AM
(Invitrogen, Eugene OR), at 250 nM from a 2.5mM stock in
DMSO. After washing, the cells were stained on ice for 30min at
5 × 107 cells/ml with α-Ly49H-AF647 (clone 3D10), α-CD49b-
PE (DX5), α-NK1.1-PerCP-Cy5.5 (pk136), and α-CD3-PE-Cy7
(17A2). The cells were then washed and stored on ice in the
dark. Subsequently, 500 µl aliquots of cells (5 × 106/ml) were
warmed to 37◦C for exactly 5min in assay buffer (dye-free RPMI
1640 with 10% FBS and 5mM HEPES). To establish the baseline
ratio of filters 379/28 and 525/50, the samples were analyzed
for 45 s on either a BD LSR-II or a BD Fortessa X20 on low
speed, each equipped with a custom-made sample heater set
to 37◦C. To this was added 8 µl of either assay buffer alone
or antibody [α-NK1.1-biotin (pk136), α-Ly49H-biotin (3D10),
or α-Ly49D-biotin (4E4)] at 500µg/ml for 45 s, followed by
32 µl of 4 mg/ml streptavidin to crosslink the receptors. After
3min, 5 µl of 200µg/ml ionomycin was added to each sample
to verify the maximum potential Ca2+ release. The percentage
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of NK cells with Ca2+ signal above the initial baseline was
calculated for a 45 s window following crosslinking, and the ratio
of this percentage in Ly49H+ to Ly49H− cells was plotted. The
peak/basal intensity and area under the curve were calculated for
a 100 second window using FlowJo.
Immunoprecipitation and Western Blotting
of Activating Receptors
Pools of NK cells from 10 to 20 mice were enriched by negative
selection using either Mojosort (Biolegend, San Diego, CA,
USA) or EasySep (Stem Cell Technologies, Vancouver, Canada)
mouse NK cell isolation kits. For some experiments, cells were
sorted at 4◦C for CD49b-BV421+, NKp46-PerCP-e710+, CD3-
AF488−, Ly49H-AF647+/Ly49H-AF647−. Cells were then lysed
in maltoside buffer (1% n-Dodecyl beta-D-maltoside, 100mM
HEPES, 150mM NaCl, 10% glycerol, pH 7.4) with Thermo Halt
protease and phosphatase inhibitors (Thermo Fisher Scientific,
Waltham, MA) for 1 h at 4◦C and 3.3 × 106 cells/ml prior to
spinning at 20,000 × g for 10min. Pierce protein A + G beads
(Thermo Fisher Scientific, Waltham, MA) were pre-saturated
with 50 µg of antibody per 500 µg of beads for 1 h at RT. After
washing the beads, the cell lysate supernatant was incubated with
the magnetic beads for 1 or 2 h at 4◦C with agitation. The beads
were then washed five times in phosphate buffered saline with
0.05% Tween-20 while the lysate was transferred to the next set
of antibody-labeled bead in the order α-Ly49H−→ α-Ly49D−→
α-NK1.1. The precipitated complexes were eluted from the beads
using Thermo Bolt sample loading dye at 37◦C for 20min,
then boiled, separated by SDS-PAGE, blotted onto nitrocellulose,
and probed with α-Dap12 rabbit polyclonal antibody gifted
by T. Takai (19, 20) or α-FcεR1γ (MilliporeSigma, Burlington,
MA, USA).
Total cell lysates were prepared and sorted as above, separated
by western blot, and probed with α-βActin (Santa Cruz
Biotechnology, Dallas, TX), α-CD3ζ (6B10.2), α-Dap12 rabbit
polyclonal antibody, or α-FcεR1γ.
Analysis of PhosphoPLCγ2
Splenocytes were stained on ice for 30min with α-Ly49H-
AF647 (clone 3D10) and α-CD49b-BV421 (clone DX5). After
washing off excess antibody, 100 µl aliquots of cells (2 ×
107/ml) were warmed to 37◦C for exactly 5min in assay
buffer (dye-free RPMI 1640 with 10% FBS and 5mM HEPES).
To this was added 50 µl of either assay buffer alone or
α-NK1.1-biotin (clone pk136) at 96µg/ml for 45 s, followed
by 50 µl of 128µg/ml streptavidin (Leinco, St. Louis, MO)
for 45 s. The reaction was quenched by the addition of
1ml of 3% paraformaldehyde in PBS for 15min. The cells
were then permeabilized with absolute methanol for 30min
on ice and stained for 1 h with α-NKp46-PerCP-eFluor710
(29A1.4), α-CD3-PE-Cy7 (17A2), α-NK1.1-PE (pk136), and
α-phosphoPLCγ2-AF488 (Y759, clone K86-689.37). The α-
phosphoPLCγ2 was purchased from Becton Dickenson (Franklin
Lakes, NJ). For experiments where α-PLCγ2 was used, the
panel was modified to also include α-PLCγ2 (Miltenyi, Bergisch
Gladbach, Germany), αNK1.1-PE-Cy7 (pk136), and α-CD3-
BV510 (17A2). Samples were analyzed on a BD Fortessa X-20 and
gated for NK cells. The GMFI of the phosphoPLCγ2 signal from
the mock-stimulated cells was subtracted from those treated by
crosslinking NK1.1, and the ratios of the phosphoPLCγ2 signals
from Ly49H+ vs. Ly49H− cells from each mouse were plotted.
Tumor Inoculation
B16-F10 melanoma cells were grown at 37◦C in a 5% CO2
incubator in DMEM media supplemented with 10% fetal bovine
serum to <70% confluency, removed with minimal exposure to
trypsin and EDTA, washed three times in PBS, and resuspended
in DMEM with 10mM HEPES. After filtering through a 40µm
mesh filter, the cells were kept on ice until use. Varying doses
of melanoma cells were injected into the lateral tail vein in 200
µl volumes. After 14 days, the lungs were harvested and fixed
in Fekete’s solution overnight. Following exchange into PBS, the
lungs were dissected into five lobes and all visible melanoma
lesions were enumerated under magnification.
The B16-F1.1 cell line was generated by passing the poorly
colonizing line B16-F1 into a WT mouse. At 14 days,
the melanoma engraftments were harvested and mechanically
homogenized using a scalpel to mince and a 40µmmesh filter to
remove large pieces of tissue. This culture was expanded in vitro
until it became morphologically homogenous.
In vivo Killing Assays
Donor splenocytes obtained from WT, m157Tg and H2Kb−/−
Db−/− (KODO) (21) mice were harvested and labeled in vitro
with different combinations of CFSE (Life Technologies),
CellTrace Violet, and CellTrace Far Red (Thermo Fisher).
Recipient mice were injected IV with 1 × 106 of each donor cell.
Spleens from recipient mice were harvested 24 h after transfer of
donor cells. NK cell-specific rejection was calculated by gating on
CD19+ transferred cells. Rejection was quantified as %Rejection
= [1–(Target/Control)/(Target/Control)Average(NKdepleted)]× 100,
where the target was the donor cell of interest, and the control
was a WT donor cell population. The ratio of target to control
cells was normalized to the average ratio recovered from NK
cell-depleted mice to calculate rejection by NK cells.
Statistics
Statistical analyses as detailed in figure legends were performed
using Prism 6 (GraphPad, San Diego, CA, USA) and Excel
(Microsoft, Redmond, WA, USA). The p-values for all figures,
except for Figure 2, were calculated using the Student’s t-test
with Welch’s correction. For Figure 2, statistical analysis was
performed using a Pearson correlation test.
RESULTS
Continuous Engagement of the Ly49H
Receptor Results in NK Cell Functional
Defects Following Stimulation Through
Both ITAM-Dependent and Independent
Activating Receptors
To investigate how continuous engagement of Ly49H alters
NK cell function, we measured intracellular levels of IFNγ and
surface-exposed Lamp1 (a surrogate marker for degranulation)
following in vitro stimulation of WT and m157Tg splenocytes
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through multiple different receptors. Representative plots of
stimulation throughNK1.1 are shown in Supplemental Figure 1.
A significantly smaller percentage of Ly49H+ NK cells from
m157Tg mice expressed Lamp1 compared to WT Ly49H+
NK cells when stimulated through NK1.1 or Ly49D alone but
not NKp46 in the presence of low levels of IL2 (Figure 1A).
A significantly smaller percentage of Ly49H+ NK cells from
m157Tg mice expressed IFNγ following stimulation through
only NK1.1 (Figure 1A). As expected, there was no difference
when we compared IFNγ or Lamp1 expression in Ly49H−
NK cells from both mice (Figure 1A). We observed the
Ly49H+/Ly49H− NK cell ratio for IFNγ and Lamp1 expression
to be lower in m157Tg mice compared to WT mice when the
splenocytes were stimulated though any of the three receptors,
as this ratio controls for variation in NK cell activation
potential between different mice (Figure 1C). Thus, continuous
engagement of the Ly49H receptor results in IFNγ production
and degranulation defects upon stimulation of these NK cells
through other ITAM-dependent activating receptors.
We also assessed NK cell function in response to stimulation
through ITAM-independent receptors including DNAM1 (in
the presence of low levels of IL2), IL2 receptor, IL15
receptor, and the combination of phorbol 12-myristate 13-
acetate (PMA) and ionomycin (Figures 1B,D). Similar to
ITAM-dependent receptors, we observed a significantly smaller
percentage of Ly49H+ NK cells expressing IFNγ or Lamp1
from m157Tg compared to WT mice following stimulation
in vitro (Figure 1B). Again, there was no difference when we
compared IFNγ or Lamp1 expression in Ly49H− NK cells from
both mice (Figure 1B). Stimulation through any of these three
ITAM-independent receptors resulted in a significantly lower
Ly49H+/Ly49H− NK cell ratio in terms of IFNγ and Lamp1
expression when comparing m157Tg and WT mice (Figure 1D).
We observed no difference when the cells were stimulated with
PMA and ionomycin, suggesting that receptor engagement is
important for the phenotype (Figures 1B,D).
To determine if functional differences were simply due to
alterations in activating receptor abundance on the cell surface,
we assessed these levels on unstimulated NK cells by flow
cytometry (Figure 1E). We also assessed the percentage of
Ly49H+ NK cells, as well as the percentage of Ly49H+ NK cells
expressing the various receptors, from WT and m157Tg mice
(Figure 1F). We did not observe a difference in the geometric
mean fluorescence intensity (GMFI) of these activating receptors
when we compared expression levels on Ly49H+ NK cells from
m157Tg and WT mice, making it unlikely that alteration in
receptor levels explains the functional differences we observed.
In addition, we did not observe a significant difference in the
percentage of NK cells expressing any of the receptors, including
Ly49H, when we comparedWT and m157Tg mice. This suggests
that the number of Ly49H+ NK cells does not change in the
m157Tg mice.
NK Cell Hyporesponsiveness Correlates
With Downmodulation of Ly49H
Engagement of the Ly49H receptor with m157 results in the
downmodulation of the receptor (7, 16, 22). In addition, we
noticed differences in Ly49H cell surface expression among
various lines of m157-expressing mice. To determine if the extent
of downmodulation of the receptor correlates with decreased NK
cell function, we compared the normalized GMFI of Ly49H to the
Ly49H+/Ly49H− NK cell ratio of IFNγ production and Lamp1
expression in response to NK1.1 engagement in various mice that
ubiquitously expressed m157 (Figures 2A,B). Due to staining
and instrument variation, we normalized Ly49H GMFI values
to the average of WT cells in a given set to allow comparisons
between experiments performed at different times. Our results
demonstrate that decreased NK cell function was associated with
the expression of lower levels of the Ly49H receptor and there
was a strong positive correlation between Ly49H expression
levels and Ly49H+ NK cell function. We hypothesize that more
extensive or frequent binding of the ligand (m157) with the
receptor (Ly49H) results in lower levels of Ly49H expression on
the NK cell and its subsequent decreased function.
NK Cells From m157Tg Mice Exhibit
Altered Calcium Flux Following
Cross-Linking of NK1.1
Altered degranulation and IFNγ production in Ly49H+ NK
cells from m157Tg mice following stimulation through various
activating receptors suggests a defect in intracellular signaling
within these NK cells. Furthermore, the administration of PMA
and ionomycin (which results in activation of protein kinase
C and the rapid increase of cytoplasmic Ca2+ concentrations,
respectively) did not alter IFNγ production or Lamp1 expression
in Ly49H+ NK cells from WT mice compared to m157Tg mice.
Since PMA and ionomycin function downstream of receptor
engagement and bypasses normal calcium flux, it suggests that
there should be a defect in calcium flux following receptor
engagement in the hyporesponsive NK cells.
To further evaluate these defects, we examined calcium flux
(quantifying the percentage of stimulated NK cells with increased
Indo-1 AM fluorescence blue shifting above resting background
levels) within the Ly49H+ and Ly49H− NK cells from WT
and m157Tg mice following cross-linking of NK1.1 and Ly49H
(Figures 3A,E). As expected, following crosslinking of NK1.1, we
observed similar levels of calcium flux in Ly49H− NK cells from
both lines (Figure 3A). However, with the same stimulation, the
Ly49H+ NK cell from m157Tg mice demonstrated decreased
calcium flux compared to Ly49H+ NK cells from WT mice.
Assessment of the Ly49H+/Ly49H− NK cell ratio of calcium flux
following the cross-linking of NK1.1, similar to our assessment
of IFNγ and Lamp1, made the effect more pronounced by
controlling for variation in NK cell activation potential between
different mice (Figure 3B). This ratio is significantly lower in
m157Tg mice, suggesting that there is a defect in calcium flux
specific to Ly49H+ NK cells from m157Tg mice.
We also measured calcium flux in Ly49H+ and Ly49H− NK
cells from WT and m157Tg mice following cross-linking of
Ly49H itself (Figures 3A,B). We would expect to see significantly
higher calcium flux in Ly49H+ NK cells from WT compared to
m157Tg mice due to the downmodulation of the Ly49H receptor
seen in Ly49H+ NK cells from m157Tg mice. In addition, the
presence of m157 binding to Ly49H in the m157Tg mice might
prevent cross-linking of the receptor. The absence of Ly49H on
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FIGURE 1 | Continuous engagement of Ly49H results in NK cell functional defects following stimulation through multiple ITAM-dependent and independent activating
receptors without altering their cell surface expression levels. (A,B) The percentage of Ly49H+ and Ly49H− NK cells expressing IFNγ or Lamp1 above background
(Continued)
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FIGURE 1 | following stimulation of WT and m157Tg splenocytes through (A) the ITAM-dependent receptors NK1.1, Ly49D, and NKp46 or (B) the ITAM-independent
receptors DNAM1, IL2, and IL15 as well as with PMA and ionomycin. (C,D) The Ly49H+/Ly49H− ratio of IFNγ or Lamp1 producing NK cells using values generated
from (A) and (B). (E) GMFI of indicated activating receptors on Ly49H+ NK cells from m157Tg and WT mice. (F) Frequency of various receptor positive NK cells from
WT and m157Tg mice. Ly49H is gated on total NK cells while all of the other receptors are gated on Ly49H+ NK cells. All results are presented as the mean ± 95% CI
(*p < 0.05; **p < 0.005; ***p < 0.0005; ns, not significant). For panels (A–F), n ≥ 5, each combined from at least two independent experiments. Each data point in
panels (C–F) represents an individual mouse.
FIGURE 2 | Defects in NK cell function correlate with downmodulation of the Ly49H receptor. The Ly49H+/Ly49H− ratio of IFNγ (A) or Lamp1 (B) producing NK cells
from 26 WT mice (black) and 45 mice that ubiquitously express m157 [7 m157Tg (red), 2 m157Tg.Low (blue), 24 UBC-Cre-ERT2 × ROSAm157Flox (purple), and 12
hCMV-Cre x ROSAm157Flox (green)] following stimulation through NK1.1 plotted against the GMFI of the Ly49H receptor normalized to WT GMFI of Ly49H on NK
cells for a given experiment. Data were collected across nine independent experiments. Each data point represents an individual mouse. The best fit lines were
generated by linear regression using Prism 6. The R2 value is shown in each panel. Correlation of the two variables was determined using a Pearson test. The Pearson
coefficients and p-values are shown in each panel.
Ly49H− NK cells from WT or m157Tg mice would prevent any
calcium flux in these NK cells. As expected, we only observed
calcium flux above background in the Ly49H+ NK cells from the
WT mice (Figure 3A).
To assess the intensity and duration of the calcium flux, we
analyzed the ratio of the peak to basal mean flux and the area
under the curve (AUC) following stimulation in Ly49H+ and
Ly49H− NK cells (Figures 3C,D). Although the peak to basal
ratio and AUC appear lower in the Ly49H+ NK cells from
m157Tg mice (Figures 3C,D), this is most likely due to the fact
that fewer Ly49H+ NK cells flux in the m157Tg mice, as shown
in Figure 3A, rather than a difference in intensity or duration.
The cells that do not flux bring down the average calcium signal
lowering the intensity peak and AUC. However, the Ly49H+ NK
cells that flux in the m157Tg mice appear to do so at a similar
intensity to Ly49H+ NK cells in the WT mice (Figure 3E).
Continuously Stimulated NK Cells Display
Altered Levels of Signaling Molecules
Involved in Ca2+ Flux
Since Ly49H+ NK cells from m157Tg mice displayed defects in
Ca2+ flux upon stimulation through NK1.1, we assessed ITAM-
associated signaling proteins involved in Ca2+ mobilization.
Phospholipase C-gamma (PLCγ), which exists in two isoforms,
is an important regulator of Ca2+ mobilization in a number of
immune cells. In NK cells, PLCγ2 appears to be the primary
isoform involved in signal transduction following activation
through engagement of certain activating receptors (23, 24).
Studies by multiple groups have demonstrated that depletion of
PLCγ2 resulted in impairment of NK cell function including
cytotoxicity, IFNγ production, and calciummobilization (23, 24).
Thus, alterations in PLCγ2 and/or phosphorylated PLCγ2 (p-
PLCγ2) levels in these NK cells could explain the altered Ca2+
flux and functional defects in the hyporesponsive NK cells.
We observed a small but statistically significant reduction
of the Ly49H+/Ly49H− ratio of the GMFIs of total PLCγ2
as well as p-PLCγ2 in unstimulated NK cells from m157Tg
compared to WT mice (Figures 4A,D). In addition, after
subtracting the steady-state background from mock stimulated
cells, we observed a further small but significant decrease in the
Ly49H+/Ly49H− ratio of p-PLCγ2 in NK cells from m157Tg
compared to WT mice following cross-linking of the NK1.1
receptor (Figures 4A,D). Finally we assessed the p-PLCγ2/
PLCγ2 ratio and observed that the ratio was the same in both
subsets of NK cells from WT and m157Tg mice following
stimulation through NK1.1 (Figure 4B). Taken together, this
suggests that reduction in total PLCγ2 is predominantly
responsible for the lower p-PLCγ2 levels seen in Ly49H+ NK cells
from m157Tg mice.
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FIGURE 3 | NK cells from m157Tg mice exhibit altered calcium flux following cross-linking of NK1.1. (A) Percentage of Ly49H+ and Ly49H− NK cells from WT and
m157Tg mice with calcium flux above background following crosslinking of the NK1.1 and Ly49H receptors. (B) The Ly49H+/Ly49H− ratios of the data from panel
(A). (C) The ratio of the peak to basal mean flux and (D) the area under the curve (AUC) following stimulation through NK1.1 and Ly49H in Ly49H+ and Ly49H− NK
cells. (E) Sample plots of Indo-1 AM Ca2+ signal vs. time in Ly49H+ and Ly49H− NK cells from WT and m157Tg mice following NK1.1 crosslinking: (a) addition of
b-pk136, (b) addition of streptavidin, and (c) addition of ionomycin. The results are presented as the mean ± 95% CI (*p < 0.05; **p < 0.005; ***p < 0.0005; ns, not
significant). Data were collected across four independent experiments. Each data point represents an individual mouse.
Zeta-chain-associated protein kinase 70 (Zap70) and
Syk are two kinases, downstream of ITAM-containing
adaptor molecules, involved in initiating the intracellular
phosphorylation cascade following engagement of certain
activating receptors on the surface of the NK cells. A prior study
identified a subset of human NK cells that expressed low levels of
the Zap70 and Syk kinases (Zap70lowSyklow) and had decreased
functional potential compared to Zap70hiSykhi NK cells. In
addition, they showed that extended NK cell activation resulted
in the loss of Zap70 and Syk (25). This suggests that extended
NK cell activation leads to low levels of Syk and Zap70, resulting
in decreased NK cell function.
To determine if loss of Zap70 or Syk plays a role in
the decreased function of Ly49H+ NK cells from m157Tg
mice, we measured intracellular level of these kinases within
Ly49H+ and Ly49H− NK cells from WT and m157Tg mice
(Figures 4C,D, Supplemental Figure 2). When we assessed the
Ly49H+/Ly49H− NK cell ratio of intracellular Syk levels, there
was a small but statistically significant decrease in m157Tg
compared to WT mice (Figure 4C). Similar to the human NK
cell subset, Syk levels appear to be lower in the Ly49H+ NK
cells from m157Tg mice, presumably because of continuous
engagement of Ly49H with m157. As opposed to the human NK
cells, we did not observe a decrease of Zap70 levels in m157Tg
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mice compared to WT mice. In fact, there was a very small but
statistically significant increase in Zap70 in Ly49H+ NK cells
from m157Tg mice (Figure 4C). Thus, continuous engagement
of Ly49H with m157 appears to decrease Syk but not Zap70 in
these NK cells.
Intracellular Levels of Adaptor Molecules
Within NK Cells Are Unchanged and
Activating Receptors Remain Associated
With Their Adaptor Molecules Following
Continuous Engagement of the Ly49H
Receptor
A previous study suggests that intracellular levels of some ITAM-
bearing adaptor molecules decrease and that they may dissociate
from their receptors following continuous engagement of an
activating receptor on the NK cell (9). Phosphorylation of the
ITAM motif within these adaptor molecules appears to create
binding sites for Syk and Zap70 (26–28). It is possible that Syk,
bound to ITAM-bearing adaptor molecules, could undergo the
same process that causes a decrease in levels of the intracellular
adaptor molecules. To determine if decreased intracellular levels
of Syk were a result of its loss due to association with ITAM-
bearing adaptor molecules, we assessed the levels of ITAM-
bearing adaptor molecules in Ly49H+ and Ly49H− NK cell
lysates from WT and m157Tg mice. We observed similar levels
of the adaptor molecules DAP12, CD3ζ, and FcRε1γ in either
Ly49H+ or Ly49H− NK cells when we compared WT and
m157Tg mice (Figure 5A). Therefore, decreases in total levels of
these particular adaptor molecules within the NK cell is unlikely
to explain the hyporesponsiveness of Ly49H+ NK cells from
m157Tg mice.
To ascertain if dissociation of the receptors with their cognate
adaptor molecules was responsible for the hyporesponsiveness
of the Ly49H+ NK cells in m157Tg mice, we examined these
associations by immunoprecipitation. We observed that NK1.1
and Ly49D remained associated with FcRε1γ and DAP12,
respectively, in Ly49H+ NK cells from both WT and m157Tg
mice (Figure 5C). Furthermore, we were able to demonstrate that
the Ly49H receptor remained associated with DAP12 in Ly49H+
NK cells from m157Tg mice when we used substantial numbers
of Ly49H+ NK cells from the m157Tg mice (Figures 5B,C).
Presumably, the requirement for more cells to detect DAP12
bound to Ly49H is due to the lower apparent expression of Ly49H
on these NK cells as assessed by flow cytometry. Alternatively,
it is possible that a low frequency of Ly49H+ NK cells remain
functional, and in these cells Ly49H remains associated with
DAP12. While we can state that the various receptors remain
associated with their respective adaptor molecules, we cannot
quantitatively compare the amounts of adaptor associated with
their receptors between the cell groups because western blot-
compatible antibodies are not available to measure loading
controls. Taken together, dissociation of adaptor molecules
from their respective activating receptors fails to adequately
explain the hyporesponsiveness of Ly49H+ NK cells from
m157Tg mice.
B16 Melanoma Clearance Is Unchanged in
m157Tg Mice
NK cells play a key role in controlling tumor growth in the
lung following tail vein injection of B16 melanoma cells into
C57Bl/6 (B6) mice (12, 29). This is an NK cell dependent model
in which depletion of NK cells results in dramatically increased
lung and liver lesions. Upon injection into mice from our colony,
the B16-F1 melanoma line, a well-established model used by
other groups (29), failed to reliably produce pulmonary lesions
(data not shown). We reasoned that, over the course of time,
drift within our colony resulted in C57Bl/6 mice that were less
permissive for growth of the B16-F1 melanoma cells. To address
this, we isolated the rare lesions from aWTC57Bl/6 in our colony
following injection with the B16-F1 melanoma cell line. This
newly selected line was designated B16-F1.1. In vivo killing of this
line is also NK cell dependent, as depletion of NK cells prior to IV
injection resulted in a significantly larger number of lung lesions
(Figure 6, Supplemental Figure 2). Following IV injection of the
B16-F1.1 melanoma cells, we observed no significant difference
in the number of lung lesions in m157Tg mice compared to
WT B6 mice (Figure 6, Supplemental Figure 2). We also tested
the widely available, more metastatic cell line B16-F10 (30).
As with the B16-F1.1 melanoma line, B16-F10 did not exhibit
any difference in lung lesion formation in m157Tg vs. WT
mice following IV injection of various numbers of the tumor
cells (Figure 6). This suggests that continuous m157/Ly49H
engagement does not meaningfully alter NK cell response to
melanoma cells in vivo.
NK Cells From m157Tg Mice Are Less
Efficient at Killing MHC Class I-deficient
Target Cells in vivo
To determine whether Ly49H+ NK cells from m157Tg mice
exhibited any measurable in vivo defects, we performed
in vivo cytotoxicity experiments to compare the function
of NK cells from WT and m157Tg mice (31, 32). These
experiments compared the killing of m157 expressing targets
(splenocytes from m157Tg mice) or MHC class I-deficient
targets (splenocytes from Kb × Db deficient mice) to WT
targets (splenocytes from WT mice) following injection into
WT or m157Tg recipient mice. As expected, WT mice,
but not m157Tg mice, effectively rejected m157Tg targets
(Figures 7A,C). Additionally, m157Tg mice were less proficient
at killing MHC class I-deficient targets when compared to WT
mice (Figures 7B,C). This suggests that continuous engagement
of m157/Ly49H generates defective NK cell responses to missing-
self in vivo.
DISCUSSION
From the data herein, combined with previously published data,
it is clear that continuous engagement of an activating receptor
on the surface of NK cells results in downmodulation of the
receptor as well as decrease in function of the NK cell in
response to other stimuli (5–8). However, the changes taking
place within the NK cell that result in its hyporesponsiveness
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FIGURE 4 | Continuously stimulated NK cells display altered levels of signaling molecules involved in Ca2+ flux. (A) The Ly49H+/Ly49H− ratio of NK cells that are
positive for intracellular PLCγ2 or phospho(Y759)PLCγ2 in WT and m157Tg mice at steady state or following crosslinking of the NK1.1 receptor. (B) The p-PLCγ2/
PLCγ2 ratio in Ly49H+ and Ly49H− NK cells from WT and m157Tg mice following stimulation through NK1.1. (C) The Ly49H+/Ly49H− ratio of NK cells that are
positive for the intracellular expression of Syk or Zap70 in WT and m157Tg mice at steady state. (D) Sample histograms of intracellular levels of indicated proteins.
Unstimulated, mock-stimulated (SA-PE only), and NK1.1-stimulated (b-pk136 → SA-PE) Ly49H+ NK cells from WT and m157Tg mice were used as indicated. Each
histogram shows isotype staining or panel minus one (PMO), WT, and m157Tg. The results are presented as the mean ± 95% CI (*p < 0.05; **p < 0.005; ***p <
0.0005). The data were collected from at least two independent experiments. Each data point represents an individual mouse.
remain unclear. Prior studies suggest a dissociation of the
activating receptor with its adaptor molecule is responsible
for the NK cell defects (9, 10). Another study suggests that
continuous engagement of activating receptor might result in the
differential expression of other activating receptors on the cell
surface (11).
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FIGURE 5 | Intracellular levels of adaptor molecules within NK cells are unchanged, and activating receptors remain associated with their adaptor molecules following
continuous engagement of the Ly49H receptor. (A) Western blot analysis of total adaptor protein levels (CD3ζ, DAP12, and FcRε1γ) in Ly49H+ and Ly49H− NK cell
lysate from WT and m157Tg mice. (B) Western blot of DAP12 following immunoprecipitation of Ly49H from cell lysates made from the HD12 cell line (BWZ cells that
overexpress Ly49H and DAP12) and the parental BWZ cell line, as well as NK-enriched splenic cells from WT and m157Tg mice. The numbers below the enriched NK
cell lanes indicate the quantity of Ly49H+ NK cells loaded. (C) Western blot of the indicated adaptor molecule following immunoprecipitation with its associated
receptor from Ly49H+ and Ly49H− splenic NK cell lysate from WT and m157Tg mice. For each of the blots, one representative of at least two experiments is shown.
Through the assessment of Ly49H+ NK cells from m157Tg
mice, where the continuous engagement of the Ly49H activating
receptor takes place, we demonstrate that NK cell functional
defects occur following stimulation through other ITAM-
dependent and independent activating receptors. These include
deficiencies in IFNγ production as well as degranulation
(Figure 1). Of note, since NKp46 and DNAM1 stimulation took
place in the presence of low levels of IL2, the observed effect
is due to a combination of the two stimuli. In addition, the
experiments described in this manuscript use total splenocytes
in the stimulation assays, so defects seen following stimulation
may not be NK cell intrinsic. Furthermore, we demonstrate
that functional deficit correlates with the extent of Ly49H
receptor downmodulation (Figure 2). Presumably, the variations
in Ly49H levels observed are due to differences in the level of
m157 expressed by the various ubiquitous promoters used to
express m157, as well as variation in the degree of induction
in the tamoxifen-inducible mice. This correlation suggests that
engagement of the receptor with the ligand is important for
eliciting the functional defect and that the frequency of the
engagement influences NK cell function.
These results support the idea of an educational “rheostat”
model of NK cell responsiveness in which the level of NK
cell function is determined by the quantity of inhibiting and
activating stimuli to which it is exposed during development
(33–36). For example, a prior study demonstrated an inverse
correlation between the levels of inhibitory receptor Ly49A
expressed on the cell surface and the frequency of IFNγ
production by Ly49A-monopositive cells stimulated through
NK1.1, suggesting that the extent of downmodulation of
Ly49A correlates with increased function (37). Compared to
the inhibitory Ly49A, we observe the opposite trend upon
engagement of the activating receptor Ly49H, in that NK cell
hyporesponsiveness correlates with increased downmodulation
of the activating receptor. To our knowledge, this represents the
first description that the magnitude of downmodulation of the
activating receptor correlates with functional defects and suggests
that, in this context, stronger activation receptor engagement
results in a larger NK cell deficit.
Prior studies show that the continuous exposure of LAK cells
to H60-expressing targets resulted in the downmodulation of
NKG2D on the cell surface of these cells. They observed that total
LAK cell lysate levels of the DAP12, DAP10, and CD3ζ proteins
were decreased in these cells and the NKG2D receptor complex
was altered such that NKG2D no longer appeared to associate
with DAP12 or DAP10 (9, 10). The findings that continuous
engagement of NKG2D altered the abundance and interaction
of multiple signaling adaptor molecules differ from what we
observed in our system.
Similar to continuous engagement of the NKG2D receptor
with H60, engagement of Ly49H with m157 results in
downmodulation of the Ly49H receptor such that the GMFI is
about 10 fold lower on Ly49H+ NK cells from m157Tg mice
compared to WT mice. However, our analysis of the total level
of adaptor molecules within the NK cell did not show any
significant difference in these proteins between Ly49H+ NK cells
from WT and m157Tg mice (Figure 5A). In addition, we show
that Ly49H, NK1.1, and Ly49D remain associated with their
respective adaptor molecules (Figures 5B,C).
One possibility for the discrepancies between the two studies
is that the NKG2D studies used LAK cells rather than primary
NK cells. The high levels of IL2 as well as the length of time in
which the cells grew in the cytokine could alter the phenotype
and receptor complexes compared to primary NK cells used in
this study. It is also possible that the interaction of NKG2D
with H60 blocked the binding of the α-NKG2D antibody to the
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FIGURE 6 | B16 melanoma clearance is unchanged in m157Tg mice. WT,
m157Tg, and NK cell-depleted WT mice were intravenously injected with
3 × 105 B16-F1.1 melanoma cells or 1 × 105 to 3 × 105 B16-F10 melanoma
cells. Mice were euthanized on day 14 and tumor nodules on the outer
surfaces of the lungs were counted. The results are presented as the mean ±
95% CI. There was no significant difference between WT and m157Tg
recipient mice under any of the conditions. The data from B16-F1.1 and
B16-F10 injections are combined from two and six independent experiments,
respectively. Each data point represents an individual mouse.
receptor, preventing the immunoprecipitation of the complex,
which could account for the absence of the adaptor molecule
in their pull-down assay. Finally, reduced levels of the NKG2D
receptor on the cell surface caused by continuous engagement
with H60 might require a larger number of these LAK cells
to immunoprecipitate the adaptor molecule. In Ly49H+ NK
cells from m157Tg mice, we demonstrate the association
of DAP12 with Ly49H only upon immunoprecipitation and
loading protein from drastically more cells than from WT
Ly49H+ (Figures 5B,C). Furthermore, we show that other
ITAM-associated activating receptors, including NK1.1 and
Ly49D, remain associated with their adaptor molecules. This
demonstrates that continuous engagement of Ly49H does not
result in either the alteration of its association with DAP12 or
the association of other activating receptors with their respective
adaptor molecules.
A recent study identified a subset of human NK cells
expressing lower levels of Syk and Zap70 kinases, which are
involved in NK cell activation through ITAM signaling. The
Zap70low/Syklow NK cells, which make up a small fraction of
NK cells, are functionally deficient in terms of degranulation
and IFNγ production in response to K562 target cells (25).
Continuous engagement of activating receptors, including
CD2 and NKp46 simultaneously or NKG2D and DNAM1
simultaneously, in vitro could induce this phenotype, suggesting
that chronic engagement of activation receptors results in
lower intracellular levels of Zap70 and Syk leading to a
subsequent hyporesponsive phenotype of the NK cells. Our
studies demonstrate a small but statistically significant decrease
in the level of Syk, but not Zap70, in Ly49H+ NK cells from
m157Tg mice. It is possible that decreased levels of Syk but
not Zap70 were seen because prior studies suggest that Syk is
essential for DAP12 signaling whereas Zap70 is not (38). An
interesting possibility is that Syk and Zap70 may compete for
binding sites on DAP12, resulting in the initiation of different
signaling pathways. The combination of decreased Syk levels
and increased Zap70 levels would decrease the likelihood of Syk
binding to the complex, altering the dominant signaling pathway
of the receptor complex.
We also note small but statistically significant decreases in
both PLCγ2 and p-PLCγ2 in Ly49H+ NK cells from m157Tg
mice compared to WT. Although small in magnitude, such
differences, particularly early in the setting of a signaling
cascade, could have large impacts on functional outcomes.
Furthermore, the total intracellular levels of these signaling
proteins were measured, not just the protein associated with the
Ly49H receptor complex, making the differences seen even more
notable. Thus, alteration of Syk and PLCγ2 levels (both signaling
molecules downstream of the adaptor molecules) might provide
a mechanism by which continuous m157/Ly49H engagement
alters other receptors’ functions.
In vivo studies of the continuous engagement of NKG2D
receptor have been performed using a transgenic model in which
the humanMICA protein is ubiquitously expressed (11). In these
experiments using redirected killing assays, chronic NKG2D
engagement resulted in impairment of killing upon stimulation
through Ly49D, and to a lesser extent NK1.1, but not NKp46.
The authors suggested altered expression of these activating
receptors as a mechanism to explain the differences. In contrast
to redirected killing, they observed increased IFNγ production by
NK cells from the MICA transgenic mice compared to non-Tg
mice upon stimulation with plate bound NK1.1 and NKp46 but
not Ly49D. Although there appear to be altered killing and IFNγ
production by NK cells, chronic engagement of NKG2D did
not appear to alter B16-F10 melanoma tumor growth following
subcutaneous injection in vivo.
There are multiple differences between our in vivo model
of continuous engagement of activating receptors and the
MICA transgenic mouse model. We observed decreased IFNγ
production as well as reduced degranulation in Ly49H+ NK
cells from m157Tg mice following cross-linking of multiple
other ITAM-dependent and independent activating receptors.
Furthermore, we did not find differences in the levels of
other activating receptors on Ly49H+ NK cells from WT or
m157Tg mice as was demonstrated in the MICA transgenic
mice. Dissimilarities might be explained by the location and level
of ligand expressed in the different transgenic mouse models.
The affinity of the receptor/ligand interaction may also play a
role. In addition, NKG2D expression occurs earlier in NK cell
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FIGURE 7 | NK cells from m157Tg mice are less efficient at killing MHC class I-deficient target cells in vivo. Donor splenocytes from three target lines were differentially
labeled with fluorescent dyes and injected into recipient mice with and without NK cell depletion. Twenty-four hours post injection, recipient spleens were analyzed for
the presence or absence of donor target cells. (A) Percentage of NK cell-specific rejection of m157-expressiong donor splenocytes by WT vs. m157Tg recipient mice.
(B) Percentage of NK cell-specific rejection of MHC class I-deficient donor splenocytes (KODO) by WT vs. m157Tg recipient mice. (C) Sample plots of donor cells
used for in vivo killing assay. Specific rejection percentages were determined using the formula: 100 × [1–(Target/WT)/(Target/WT)Average(NKdepletedWT)]. The results
are presented as the mean ± 95% CI (***p < 0.0005), and are combined from three independent experiments. Each data point represents an individual mouse.
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development compared to Ly49H (39–41). Finally, our study
identified NK cells as NKp46+, CD49b+, and CD3−, while
the MICA transgenic mouse study identified them as CD49b+,
CD3−. All of these differences could influence how continuous
receptor engagement alters NK cell function and explain the
discrepancies between the two models.
Other studies suggest that continuous engagement of an
activation receptor on NK cells results in defects in melanoma
tumor rejection. Specifically, recombinant soluble MULT1 could
stimulate rejection of subcutaneous injected melanoma cells,
presumably by reversing the hyporesponsiveness of NK cells
resulting from the engagement of the NK cell with an
endogenously expressed NKG2D ligand on tumor-associated
cells (15). We did not observe a difference in the development of
lung lesions following IV melanoma injection in m157Tg vs. WT
littermates (Figure 6), even though there were functional defects
in Ly49H+ NK cells from m157Tg mice following stimulation
through DNAM1, an activating receptor involved in NK cell
response to melanoma cells (Figure 1B). There are several
possible explanations for the differences in NK cell response
in the two systems. In our model, only the Ly49H+ NK cells,
which represents about 35% of the NK cell population, are
defective. Just as the Ly49H− NK cells, which do not interact
with m157, exhibit no variation between WT and m157Tg in
plate-bound antibody activation assays, we would expect that the
Ly49H− NK cells should not have any defects and be fully able
to participate normally in the killing of the melanoma cells. In
addition, engagement of ligand with receptor in our transgenic
system was a result of the ubiquitous expression of the ligand,
as opposed to the soluble MULT1 experiments, where the ligand
was endogenously expressed and not transgenic. Although we did
not see an in vivo response to the administration of melanoma
cells, we observed that continuous Ly49H engagement alters the
in vivo NK cell response to target cells that have downregulated
MHC class I (missing- self).
NK cell responses to tumor cells result from interactions that
take place between ligands expressed on cells within the tumor
environment and the receptors expressed on the NK cells, such
as inhibitory receptors that can bind MHC class I molecules and
activating receptors that can bind stress-induced ligands. Tumors
cells can decrease the expression of MHC class I on their surface
in order to evade the adaptive immune system (42). In doing so,
tumors becomemore susceptible to killing by NK cells due to loss
of engagement with inhibitory receptors. We demonstrate that
not only does continuous engagement of an activating receptor
result in defects in IFNγ and degranulation when the NK cell is
stimulated through other activating receptors in vitro, but there
is also a defect in killing cells that have lost expression of MHC
class I in vivo. This could have a major impact on the ability of
NK cells to kill tumor cells in the tumor microenvironment.
A study analyzing peritoneal fluid NK cells from patients with
ovarian cancer noted that tumor-associated NK cells expressed
lower levels of several receptors, including DNAM1, compared
to NK cells from the peripheral blood, and these peritoneal
NK cells were hyporesponsive in killing HLA class I deficient
targets. Furthermore, incubation of NK cells with ovarian
cancer cells expressing the DNAM1 ligand CD155 resulted in
downmodulation of DNAM1 on the NK cells (43). This suggests
that chronic engagement of an activating receptor expressed on
tumor-associated NK cells may hamper immune surveillance
and promote tumor growth. In fact, reduced surface expression
of DNAM1 and NKG2D has been associated with defective
NK cell cytotoxicity and cytokine production in patients with
various types of advanced cancer (44–47). Furthermore, studies
show that glioblastoma cells produce lactate dehydrogenase 5,
which can induce the expression of NKG2D ligands on both
tumor-infiltrating myeloid cells and circulating monocytes. This
results in the chronic engagement of the NKG2D receptor on
NK cells and downmodulation of the NKG2D receptor (48).
It is possible that upregulation of NKG2D ligands within the
tumor environment results in continuous engagement of the
activating receptor NKG2D on the intra-tumorNK cells and their
subsequent hyporesponsiveness. Blocking this type of continuous
engagement, as suggested by the soluble MULT1 experiments,
may prevent NK cell hyporesponsiveness (15, 49, 50).
Of note, ITAM bearing adaptor molecules appear to be
capable of mediating inhibitory signals in myeloid derived cells
(51, 52). In fact, the DAP12 adaptor molecule, associated with
multiple NK cell activating receptors including Ly49H, can act to
mediate inhibitory signals in osteoclast and macrophages (51, 53,
54). Whether the ITAM motif is activating or inhibitory might
depend on the strength of the interaction of the receptor with the
ligand, the cell type that expresses the ligand, as well as the length
of time the interaction takes place. The potential mechanisms by
which it can alter signaling through other activating receptors
include the sequestration of a critical component involved in
signaling by the other receptor as well as possibly the recruitment
of a phosphatase to the complex which dephosphorylates the
signaling cascade of the other receptor (53). It is possible that
similar changes are taking place in NK cells following continuous
engagement of the activating receptor.
The continuous engagement of the Ly49H receptor appears
to result in modification of the downstream signaling cascade
that alters effector response to stimulation by other ITAM-
dependent and independent receptors. In addition, there are
defects in the NK cell ability to respond to missing-self. These
mechanisms likely play a role in how NK cells respond to
both tumor cells and virally infected cells, two scenarios in
which downmodulation of MHC class I takes place. This makes
understanding the mechanisms by which continuous activation
receptor engagement results in defective NK cell function
an important prerequisite for the development of potential
new therapies to make NK cells more efficient at eliminating
tumor cells.
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